Form 4: uniQure Director Jeremy Springhorn Granted Significant Equity Awards

uniQure N.V. Director Jeremy P. Springhorn was granted 7,970 restricted share units and 15,630 stock options as part of his compensation, aligning his interests with the company's long-term performance.

Summary

• Jeremy P. Springhorn, a Director of uniQure N.V. (QURE), reported new equity awards on June 11, 2025.
• He was granted 7,970 Restricted Share Units (RSUs) under the Issuer's 2014 Share Incentive Plan, with a grant price of $0.
• Each RSU represents the contingent right to receive one Ordinary Share.
• These RSUs will vest 100% on June 11, 2026, subject to his continued relationship with uniQure.
• Following this transaction, Springhorn beneficially owns 39,806 Ordinary Shares.
• Additionally, he was granted 15,630 Stock Options with an exercise price of $16.22 per share.
• These stock options will also vest 100% on June 11, 2026, contingent on his continued relationship with the Issuer.
• The stock options have an expiration date of June 11, 2035.
• After this transaction, Springhorn beneficially owns 15,630 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports standard equity compensation for a director, which is a positive sign of alignment between management and shareholder interests. It does not contain negative news or significant risks beyond the inherent market risks of holding equity.

Positives

• The grant of Restricted Share Units and Stock Options aligns the Director's interests with long-term shareholder value creation.
• Equity compensation is a common practice to incentivize key personnel and retain talent.
• The vesting schedule encourages continued commitment to the company.

Risks

• The value of the granted equity awards is subject to the future performance of uniQure N.V.'s stock price.
• Vesting of the awards is contingent on the Director's continued relationship with the Issuer, meaning forfeiture if the relationship ceases before vesting.

Future Outlook

The document does not provide a future outlook for the company's performance, but the equity grants imply a long-term commitment from the director. The vesting schedule indicates that the director's full benefit from these awards will materialize one year from the grant date, contingent on continued employment.

Industry Context

Equity compensation, including RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries (where uniQure operates) to attract, retain, and incentivize key executives and directors, aligning their interests with long-term company growth and shareholder returns.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) and Stock Options as part of executive compensation is a common and widely accepted practice across the biotechnology and pharmaceutical sectors, similar to companies like BioNTech, Moderna, or Regeneron.
• The vesting schedule of 100% on the first anniversary of the grant date is a relatively short-term vesting period for some equity awards, though it is not uncommon for director grants which may be annual. Longer vesting periods (e.g., 3-4 years) are often seen for executive performance-based awards.
• The exercise price of $16.22 for the stock options would typically be the closing price of uniQure N.V. shares on the grant date, which is standard practice to ensure compliance with tax and accounting rules.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance. Dilution from future share issuance upon vesting/exercise is a minor consideration.
• Employees: No direct impact mentioned, but it reflects the company's compensation philosophy for key personnel.

Next Steps

• The Restricted Share Units and Stock Options are scheduled to vest on June 11, 2026, subject to the Director's continued relationship with uniQure N.V.
• The Director may exercise the stock options at any time after vesting until their expiration on June 11, 2035.

Key Dates

Keywords

uniQure N.V., QURE, SEC Form 4, Insider Trading, Equity Compensation, Restricted Share Units, Stock Options, Director Compensation, Share Incentive Plan, Beneficial Ownership